These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25948299)

  • 1. [Development of mogamulizumab and establishment of an optimal therapy based on genomic biomarkers: from the academic viewpoint].
    Iida S; Ishida T; Ueda R
    Yakugaku Zasshi; 2015; 135(5):663-9. PubMed ID: 25948299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
    Ogura M; Ishida T; Hatake K; Taniwaki M; Ando K; Tobinai K; Fujimoto K; Yamamoto K; Miyamoto T; Uike N; Tanimoto M; Tsukasaki K; Ishizawa K; Suzumiya J; Inagaki H; Tamura K; Akinaga S; Tomonaga M; Ueda R
    J Clin Oncol; 2014 Apr; 32(11):1157-63. PubMed ID: 24616310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas.
    Moore DC; Elmes JB; Shibu PA; Larck C; Park SI
    Ann Pharmacother; 2020 Apr; 54(4):371-379. PubMed ID: 31648540
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis.
    Yonekura K; Kanzaki T; Gunshin K; Kawakami N; Takatsuka Y; Nakano N; Tokunaga M; Kubota A; Takeuchi S; Kanekura T; Utsunomiya A
    J Dermatol; 2014 Mar; 41(3):239-44. PubMed ID: 24628073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of mogamulizumab in relapsed or refractory CC chemokine receptor 4-positive peripheral T-cell lymphoma and relapsed or refractory cutaneous T-cell lymphoma: A post-marketing surveillance in Japan.
    Ishitsuka K; Yasukawa T; Tsuji Y
    Hematol Oncol; 2024 Jul; 42(4):e3292. PubMed ID: 38847317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Application of Anti-CCR4 Monoclonal Antibody.
    Ueda R
    Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of mogamulizumab in adult T-cell leukemia/lymphoma in clinical practice.
    Sekine M; Kubuki Y; Kameda T; Takeuchi M; Toyama T; Kawano N; Maeda K; Sato S; Ishizaki J; Kawano H; Kamiunten A; Akizuki K; Tahira Y; Shimoda H; Shide K; Hidaka T; Kitanaka A; Yamashita K; Matsuoka H; Shimoda K
    Eur J Haematol; 2017 May; 98(5):501-507. PubMed ID: 28152225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma.
    Ishii T; Ishida T; Utsunomiya A; Inagaki A; Yano H; Komatsu H; Iida S; Imada K; Uchiyama T; Akinaga S; Shitara K; Ueda R
    Clin Cancer Res; 2010 Mar; 16(5):1520-31. PubMed ID: 20160057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
    Remer M; Al-Shamkhani A; Glennie M; Johnson P
    Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
    Shiratori S; Ohhigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
    Hematol Oncol; 2017 Mar; 35(1):138-140. PubMed ID: 26177633
    [No Abstract]   [Full Text] [Related]  

  • 12. Mogamulizumab for the treatment of adult T-cell leukemia/lymphoma.
    de Lartigue J
    Drugs Today (Barc); 2012 Oct; 48(10):655-60. PubMed ID: 23110261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance.
    Ishitsuka K; Yurimoto S; Kawamura K; Tsuji Y; Iwabuchi M; Takahashi T; Tobinai K
    Int J Hematol; 2017 Oct; 106(4):522-532. PubMed ID: 28597329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
    Winsett FT; Lewis DJ; Duvic M
    Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mogamulizumab for the treatment of T-cell lymphoma.
    Makita S; Tobinai K
    Expert Opin Biol Ther; 2017 Sep; 17(9):1145-1153. PubMed ID: 28649848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
    Zhang T; Sun J; Li J; Zhao Y; Zhang T; Yang R; Ma X
    BMC Cancer; 2021 May; 21(1):618. PubMed ID: 34039310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies.
    Ishida T; Utsunomiya A; Jo T; Yamamoto K; Kato K; Yoshida S; Takemoto S; Suzushima H; Kobayashi Y; Imaizumi Y; Yoshimura K; Kawamura K; Takahashi T; Tobinai K; Ueda R
    Cancer Sci; 2017 Oct; 108(10):2022-2029. PubMed ID: 28776876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas.
    Tobinai K; Takahashi T; Akinaga S
    Curr Hematol Malig Rep; 2012 Sep; 7(3):235-40. PubMed ID: 22538464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia.
    Mohammed TO; Chagan-Yasutan H; Ashino Y; Nakayama W; Takahashi Y; Shimomura T; Fujimoto T; Watanabe Y; Niki T; Suzushima H; Hattori T
    Tohoku J Exp Med; 2017 Mar; 241(3):201-208. PubMed ID: 28321034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.